Eye On Delta, Sanofi/GSK To Begin India Trials Of COVID-19 Vaccine

Pfizer/BioNTech Look At Booster Shots

09 Jul 2021

Sanofi and GSK, which are in the middle of Phase III global trials for their COVID-19 vaccine candidate, plan to test the contender against all variants of concern including the highly contagious Delta variant, Scrip has learned. Meanwhile, Pfizer/BioNTech is looking at a booster to combat lower efficacy/effectiveness against this variant.

PS2004_Clinical Trials_1095927122_1200.jpg — COVID-19 Vaccine Clinical Trials Are Gearing To Counter Variants • Source: Shutterstock

Sanofi and GlaxoSmithKline plc, which are in the middle of Phase III global trials for their recombinant protein COVID-19 vaccine candidate, plan to test the contender against the Delta variant as well, a Sanofi spokesperson has told Scrip.

India witnessed a surge of COVID-19 cases as the Delta variant took hold, with high mortality reported during the second wave

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

15 May 2025

• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.